The proportion of medical IT and information technology in China's medical health investment is still low, but from the perspective of the number and type of startups, it has maintained a vigorous growth trend. In contrast to US data, in 2009-2015, a total of $10 billion was invested in 500 medical IT startups. Even though the medical systems of the two countries are very different, from the perspective of China's medical reform direction, reform speed and intensity in the past 10 years, the reform has penetrated into many aspects such as hospital services, medical innovation, and medical device support. I believe that the reform of medical IT is fast-paced. ongoing.

The ugly words are written in front, and the reasons for the difficult growth of medical IT are. In other words, what kinds of traps a startup needs to avoid in order to stay young and be invincible. Looking back at the 500 medical IT companies, there are very few successful ones.

2B or 2C?

It is not good to get sick. Being sick is often associated with pain, ugliness, and sadness. Everyone can get sick, but it doesn't mean everyone has the enthusiasm to spend on the disease. The reason is simple: no one likes to get sick. A person can only think of 'health health' when he has to. This is doomed to the effect of viral transmission on the medical 2C end, and the retention rate is terrible. (Maybe medical beauty, maternity is an exception). Therefore, social platforms for chronic diseases and basic health protection categories are mostly not good.

On the other hand, consumers are really willing to pay for medical services and are not sensitive to price. Especially in the case of information asymmetry, or where the patient and the payer are not alone. However, most cases tend to be short-term treatments, such as trauma recovery, severe treatment (such as cancer, cardiovascular disease, etc.). And, medical care is a disease of thousands or perhaps tens of thousands of separate categories. The group of patients with stage 3 breast cancer, liver occupying, high blood pressure, and diabetes is simply a different group. There is no intersection and no match. This led to a fragmented, micro-community ending. The company only makes up for the retention cost and the lost cost by increasing the retention rate.

Even worse, even people with chronic conditions feel good most of the time. If you go to see a doctor once every six months or a year, it will be good to adjust the medicine. Some patients may not associate side effects with drugs even if they have adverse reactions, and will not take the initiative to change drugs. Chronic diseases account for most of the medical expenses, but often patients are cautious when buying new instruments, changing other types of medicines, changing services, and moving very slowly. Numerous apps such as medication reminders, symptom detection, biosensors, patient education, etc. are not hot. Even a company as famous as PatientsLikeme is basically just a group of people complaining about the misfortunes and symptoms of illness, bringing negative emotions and having a wide-lasting influence.

If you want to do 2C, you must think about what problems have been solved for the people.

Perhaps safer is to focus on the 2B field. This is especially true in the United States. In the US medical system, most of the expenses are still borne by the employer. The self-pay ratio is relatively low and has a ceiling. Chronic diseases and emergency patients often exceed the upper limit. In addition, 2B also makes up for the characteristics of no virus transmission, and deep cultivation in the vertical field, the retention rate is high, and the repurchase rate is guaranteed. Large companies are also very good channel partners, which can speed up the reach of users and reduce the cost of getting customers. But of course this is not perfect. 2B's sales cycle and sales cost are also very expensive. Explained in detail below. In China, 2B is not as mature as 2C, but it is also worthy of attention. With the reform of the payment policy, this change may come very quickly and very fiercely.

Safinamide Mesylate Intermediate

Safinamide Mesylate Intermediate,Safinamide Mesylate,Safinamide Mesylate Api,Safinamide Mesylate Cas 202825-46-5

Shandong Bolode Bio-technology Co., Ltd. , https://www.bldpharma.com